Akebia Ther (AKBA) - Total Assets
Based on the latest financial reports, Akebia Ther (AKBA) holds total assets worth $376.56 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Akebia Ther service its debt to assess how comfortably operating cash covers total debt obligations.
Akebia Ther - Total Assets Trend (2012–2025)
This chart illustrates how Akebia Ther's total assets have evolved over time, based on quarterly financial data. See AKBA total equity for net asset value and shareholders' equity analysis.
Akebia Ther - Asset Composition Analysis
Current Asset Composition (December 2025)
Akebia Ther's total assets of $376.56 Million consist of 49.1% current assets and 50.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 49.1% |
| Accounts Receivable | $47.03 Million | 12.5% |
| Inventory | $15.61 Million | 4.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $59.04 Million | 15.7% |
Asset Composition Trend (2012–2025)
This chart illustrates how Akebia Ther's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see AKBA market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Akebia Ther's current assets represent 49.1% of total assets in 2025, a decrease from 100.0% in 2012.
- Cash Position: Cash and equivalents constituted 49.1% of total assets in 2025, down from 73.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 15.7% of total assets.
Akebia Ther Competitors by Total Assets
Key competitors of Akebia Ther based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.39 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
Akebia Ther - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.13 | 1.41 | 2.11 |
| Quick Ratio | 1.04 | 1.21 | 1.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $21.91 Million | $32.92 Million | $192.34 Million |
Akebia Ther - Advanced Valuation Insights
This section examines the relationship between Akebia Ther's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.51 |
| Latest Market Cap to Assets Ratio | 0.90 |
| Asset Growth Rate (YoY) | 70.6% |
| Total Assets | $376.56 Million |
| Market Capitalization | $340.21 Million USD |
Valuation Analysis
Near Book Valuation: The market values Akebia Ther's assets close to their book value (0.90x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Akebia Ther's assets grew by 70.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Akebia Ther (2012–2025)
The table below shows the annual total assets of Akebia Ther from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $376.56 Million | +70.65% |
| 2024-12-31 | $220.67 Million | -8.70% |
| 2023-12-31 | $241.70 Million | -32.12% |
| 2022-12-31 | $356.05 Million | -32.74% |
| 2021-12-31 | $529.35 Million | -17.82% |
| 2020-12-31 | $644.14 Million | -16.48% |
| 2019-12-31 | $771.20 Million | -22.61% |
| 2018-12-31 | $996.54 Million | +173.59% |
| 2017-12-31 | $364.25 Million | +21.33% |
| 2016-12-31 | $300.22 Million | +110.03% |
| 2015-12-31 | $142.94 Million | +28.78% |
| 2014-12-31 | $111.00 Million | +220.19% |
| 2013-12-31 | $34.66 Million | +1444.87% |
| 2012-12-31 | $2.24 Million | -- |
About Akebia Ther
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and … Read more